Transthyretin Amyloidosis Treatment Market By Drug (Inostersen, Partisiran, Tafamidis, and Others), By Indication (Wild Type ATTR Amyloidosis, and Hereditary ATTR Amyloidosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Region - Market Trends, Analysis, and Forecast till 2034

Transthyretin Amyloidosis Treatment Market accounted for USD 40.5 Million in 2019 and is anticipated to register a CAGR of 58.7%.

Transthyretin amyloidosis may be a rare progressive fatal disease that destroys the nerve cells controlling various bodily functions. The symptoms of the disease are almost like those of the many other diseases. Moreover, patients affected by the condition die ten years after the onset of symptoms. Therefore, timely symptom identification, diagnosis, and treatment are important. Transthyretin amyloidosis is caused due to the misfolding of the transthyretin (TTR) protein, which may be a secondary transporter of thyroxine and retinol-binding protein. The misfolding causes protein depositions referred to as amyloids to make within tissues and organs. There are three types of transthyretin amyloidosis. In familial amyloid polyneuropathy (TTR-FAP) amyloids cause damage of the nerves that control the senses, movement, and involuntary bodily functions. The second type is transthyretin amyloidosis cardiomyopathy (TTR-CM) that results in cardiomyopathy. It causes damage to the heart’s muscles, inhibiting the power to pump blood throughout the body. The third type is senile systemic amyloidosis (SSA), which is more prevalent in men than women.

Increasing prevalence of transthyretin amyloidosis

The transthyretin amyloidosis treatment market is likely to be driven by an increase in the prevalence of disease, rise in the population with African origin, increase in awareness, improvement in diagnostic procedures, improving health care services, rapid economic growth in developing countries, and rise in research and development activity. For instance, According to the Amyloidosis Foundation, there are roughly 126 different genetic variations in ATTR, with up to 53 types of genetic variations in non-transthyretin hereditary amyloidosis diseases. According to reports published on transthyretin amyloidosis, it has been estimated that nearly 10,000, or 1.1 per 100,000 individuals in the world are living with TTR-FAP. The age group of patients suffering from the disorder is between 30 and 40 years of age. It has also been observed that TTR-CM tends to affect older males aged 65 years and above. Familial amyloid polyneuropathy (TTR-FAP) leads to 100 different types of mutations in the transthyretin gene, which leads to protein misfolding. There is only a 50% chance of transferring the mutation to the next generation from an affected parent. On the other hand, the mutation that leads to familial amyloid cardiomyopathy is generally found in individuals of African origin. Amyloidosis related to age primarily affects Caucasian men who are aged 65 years and above.

Increasing healthcare awareness among people

The global ATTR market is likely to exhibit a robust growth during the forecast period due to the probability of rising number of ATTR therapeutic drugs launches, increasing African-American population as they are genetically susceptible to amyloidosis, increasing healthcare awareness among people, and rising average income of individuals. However, the growth of this market can be hindered by stringent regulatory policies, the high cost of ATTR drugs, and incorrect diagnosis of ATTR disorders and limitations of clinical trials. Lack of knowledge about this condition and unavailability of advanced diagnostic methods in the middle-income countries are the major challenges to the market.

Transthyretin amyloidosis treatment market is segmented based on drug, indication, distribution channel, and region.

On the basis of drug, the transthyretin amyloidosis treatment market is segmented into inostersen, partisiran, tafamidis, and others. Based on indication, the target market is segmented into wild type ATTR amyloidosis, and hereditary ATTR amyloidosis. Based on distribution channel, the target market is segmented into retail pharmacy, hospital pharmacy, and online pharmacy.

Regional Insights:

On region the transthyretin amyloidosis treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North Americas dominates the market for Transthyretin (TTR) amyloidosis owing to the increasing prevalence of amyloidosis among adults and older population and rising geriatric population which is a major trigger factor for this disease. For instance, according to a report published by ASCO Journal in 2016 around 4,000 people developed amyloidosis each year in the United States. Thus, this rising patient pool is going to boost up the market growth during the forecast period. Additionally, factors such as increasing government initiatives and funding for research, development in advanced medical treatment options, and rising use of technologically advanced medical diagnostic devices are likely to drive the market. The presence of pharmaceutical giants such as Pfizer, Merck, etc. also propels the market growth in this region.

Report Scope:

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2034. For the purpose of this study, has segmented the transthyretin amyloidosis treatment market report based on drug, indication, distribution channel, and region.

Transthyretin Amyloidosis Treatment Market, By Drug:

• Inostersen
• Partisiran
• Tafamidis
• Others

Transthyretin Amyloidosis Treatment Market, By Indication:

• Wild Type ATTR Amyloidosis
• Hereditary ATTR Amyloidosis

Transthyretin Amyloidosis Treatment Market, By Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

Transthyretin Amyloidosis Treatment Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the transthyretin amyloidosis treatment market includes Prothena Corporation plc., Pfizer Inc., Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Celgene Corporation, Takeda Pharmaceutical Company Ltd., Johnson and Johnson Pvt. Ltd., GlaxoSmithKline plc, Alnylam Pharmaceuticals Inc., SOM Innovation Biotech S.L., AstraZeneca plc. The market is especially characterized by collaborations and partnerships between the businesses and acquisitions of smaller players as a part of strategic expansion as well as launching their new product specimen. For instance, In August 2018, Alnylam Pharmaceuticals, Inc. received the U.S. Food and Drug Administration (FDA) approval for its ONPATTRO (patisiran) lipid complex injection— a RNA interference (RNAi) therapeutic— indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

• Prothena Corporation plc.
• Pfizer Inc.
• Ionis Pharmaceuticals Inc.
• Valeant Pharmaceuticals International Inc.
• Celgene Corporation
• Takeda Pharmaceutical Company Ltd.
• Johnson and Johnson Pvt. Ltd.
• GlaxoSmithKline plc
• Alnylam Pharmaceuticals Inc.
• SOM Innovation Biotech S.L.
• AstraZeneca plc.